Neurovalens

Pioneers in non-invasive
medical technology

Brainstem stimulation to treat global health epidemics.

Learn More
Science

Re-Engineering
Your Brain

How does the neural network affect type 2 diabetes, insomnia, obesity and anxiety.

Learn More
Play

Solving some of the world’s greatest health challenges

Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world’s greatest health challenges.

Our medical device technology offers unparalleled transdermal activation of the homeostatic nuclei of the brainstem and hypothalamus, allowing for alterations in autonomic function, circadian regulation and Neuro-metabolic influence.

Our core values hinge on the generation of robust clinical data that provide meaningful outcomes throughout the lives of our patients. Neurovalens technology aims to provide drug-free solutions to the worlds, greatest health epidemics.

Jason | Neurovalens

Merging Neuroscience & Technology

Applications for Neurovalens Technology

Type 2 Diabetes / Obesity

Primary Target:

Central Melanocortin System (CMCS) & Arcuate Nucleus (Hypothalamus)

Secondary Target:

Dorsal Motor Nucleus of Vagus & Nucleus of the Solitary Tract (Brainstem)

Our goal in type 2 diabetes is to improve glucose and insulin regulation and therefore positively influence HbA1c. Optimization of the central melanocortin system and regulation of the vagal nerve afferents are the primary target areas to allow better glycemic control and potentially reduce the need for pharmaceuticals. Poor regulation of metabolic homeostasis drives the development of obesity. Neurovalens targets key hypothalamic and brainstem nuclei involved in the neuro-regulation of body composition, with the aim of improving this dysregulation at source.

Insomnia

Primary Target:

Suprachiasmatic Nucleus (SCN) (Hypothalamus)

Secondary Target:

Intergeniculate Leaflet (IGL) (Thalamus)

Homeostatic centers within the hypothalamus and thalamus regulate the circadian rhythm the and sleep wake cycle. Neurovalens’ technology actively stimulates the SCN and IGL in a way that improves both sleep quality and duration.

Anxiety

Primary Target:

Locus Coeruleus (LC) (Brainstem)

Secondary Target:

Paraventricular Nucleus (PVN) (Hypothalamus)

Regulation of the parasympathetic and sympathetic pathways of the autonomic nervous system in response to stress can be influenced via the LC and the PVN. Connections to these centers via the medial vestibular nucleus allow both to be non-invasively targeted.